Stock listing

NASDAQ:ALGS Aligos Therapeutics, Inc. Stock

Home listing (NASDAQ) of Aligos Therapeutics, Inc.

Follow Aligos Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ALGS

$1.22 USD -0.08 (-6.2%)

Close on Nov 20, 2026

Past year -85.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.18 – $1.34 USDNov 20, 2026
Volume
105,409 sharesNov 20, 2026
Market cap
$6.64M USDAt the close on Nov 20, 2026 · price × 5.44M shares outstanding
52-week range
$1.18 – $13.69 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$254,362 USDMedian day 42,100 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Aligos Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ALGS · Home$1.22 USD-0.08 (-6.2%)105,409$1.26$1.336$1.175$1.30Close on Nov 20, 2026
Frankfurt:5WK0€1.138 EUR-0.044 (-3.7%)190€1.106€1.138€1.106€1.182Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ALGS · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.22-0.08-6.2%$1.26$1.336$1.175105,409
$1.30-0.06-4.4%$1.39$1.58$1.25109,147
$1.36-0.30-18.1%$1.63$1.63$1.3657,117
$1.66-0.44-21.0%$2.00$2.00$1.58139,603
$2.10+0.12+6.1%$2.09$2.245$1.9857,515
$1.98-0.18-8.3%$2.21$2.316$1.92120,576
$2.16-0.41-16.0%$2.79$2.81$2.02283,400
$2.57-1.38-34.9%$3.99$3.99$2.56194,200
$3.95-0.12-2.9%$4.25$4.65$3.95141,300
$4.07-0.44-9.8%$4.44$4.855$4.00101,700
$4.51-0.51-10.2%$5.004$5.004$4.50540,200
$5.02+0.27+5.7%$4.89$5.14$4.72127,800
$4.75+0.15+3.3%$4.65$4.95$4.6513,900
$4.60-0.20-4.2%$4.81$4.99$4.6023,000
$4.80-0.23-4.6%$4.99$5.05$4.7523,800
$5.03-0.14-2.7%$5.02$5.375$5.0247,200
$5.17+0.43+9.1%$4.66$5.26$4.6623,500
$4.74+0.09+1.9%$4.67$4.81$4.639,500
$4.65-0.13-2.7%$4.98$4.98$4.5533,000
$4.78-0.04-0.8%$4.76$4.92$4.654,800
$4.82-0.14-2.8%$5.005$5.005$4.7815,300
$4.96-0.07-1.4%$4.88$5.235$4.8813,100
$5.03+0.19+3.9%$4.74$5.241$4.7442,800
$4.84-0.02-0.4%$4.95$5.08$4.6182,000
$4.86-0.53-9.8%$5.32$5.50$4.8667,600
$5.39+0.16+3.1%$5.40$5.409$5.18625,500
$5.23-0.28-5.1%$5.50$5.60$5.2160,600
$5.51-0.02-0.4%$5.465$5.60$5.2034,000
$5.53+0.19+3.6%$5.50$5.64$5.3057,300
$5.34+0.03+0.6%$5.27$5.442$5.278,900
$5.31-0.01-0.2%$5.25$5.53$5.0837,400
$5.32-0.06-1.1%$5.33$5.525$5.2319,400
$5.38-0.02-0.4%$5.46$5.53$5.3112,800
$5.40-0.14-2.5%$5.57$5.65$5.3548,600
$5.54+0.04+0.7%$5.58$5.72$5.3729,000
$5.50-0.13-2.3%$5.69$5.74$5.36728,300
$5.63+0.01+0.2%$5.65$5.80$5.5435,300
$5.62+0.08+1.4%$5.53$5.68$5.4011,500
$5.54+0.03+0.5%$5.38$5.54$5.1879,500
$5.51-0.04-0.7%$5.70$5.765$5.4745,000
$5.55-0.01-0.2%$5.55$5.695$5.2759,600
$5.56-0.12-2.1%$5.72$5.936$5.4535,100
$5.68+0.19+3.5%$5.57$6.30$5.22275,700
$5.49+0.25+4.8%$5.31$5.88$5.21125,000
$5.24+0.07+1.4%$5.15$5.25$5.01521,300
$5.17+0.12+2.4%$5.10$5.29$5.1021,700
$5.05+0.06+1.2%$5.01$5.13$4.9341,700
$4.99-0.05-1.0%$5.04$5.445$4.8234,100
$5.04-0.18-3.4%$5.17$5.27$5.0228,000
$5.22-0.11-2.1%$5.39$5.502$5.1437,000
$5.33-0.17-3.1%$5.38$5.48$5.2146,100
$5.50-0.26-4.5%$5.79$6.02$5.4133,000
$5.76-0.45-7.2%$6.21$6.34$5.6263,600
$6.21-0.01-0.2%$6.16$6.21$6.0220,300
$6.22+0.01+0.2%$6.22$6.48$6.0742,100
$6.21+0.12+2.0%$6.15$6.64$6.0155,200
$6.09+0.23+3.9%$5.76$6.22$5.61101,600
$5.86-1.05-15.2%$6.83$6.83$5.8698,700
$6.91-0.16-2.3%$7.025$7.10$6.6439,100
$7.07-0.44-5.9%$7.44$7.495$6.8280,300
$7.51+0.04+0.5%$7.37$7.72$7.0468,900
$7.47+0.54+7.8%$6.93$7.538$6.7193,400
$6.93+0.26+3.9%$6.61$7.00$6.4033,200
$6.67+0.23+3.6%$6.48$6.799$6.4052,300
$6.44-0.45-6.5%$6.77$7.006$6.3562,500

Splits

1 split · NASDAQ:ALGS · every price before a split is adjusted for it

DayRatioWhat
1-for-25Consolidation
Ticker
NASDAQ:ALGS
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Aligos Therapeutics, Inc. news

Aligos Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
22 in the last 12 months · 135 in all · newest Nov 6, 2026 · oldest 2020
Decks
34 decks · latest March 2025

Where Aligos Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ALGS · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ALGSBOATSUnited StatesUSD
gettex:5WK0gettexGermanyEUR
LS Exchange:A40LQ4LS ExchangeGermanyEUR
Lang & Schwarz:A40LQ4Lang & SchwarzGermanyEUR
Tradegate:5WK0TradegateGermanyEUR
Dusseldorf:5WK0DusseldorfGermanyEUR
Frankfurt:5WK0FrankfurtGermanyEUR
Munich:5WK0MunichGermanyEUR
Stuttgart:5WK0StuttgartGermanyEUR

Valuation

EV/sales −2.1× against a median of 2.8×: 2nd lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$12.55M USD
P/E
Loss
EV/sales
−2.1×
EV/EBITDA
Negative EBITDA
Price/book
0.6×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
1.1×
Beta vs S&P 500
1.63

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Aligos Therapeutics, Inc. · NASDAQ:ALGSUS$6.64M−US$12.55Mn/a−2.1×n/a0.6×n/a1.1×1.63
Arctic Bioscience AS · OSL:ABSUS$7.00MUS$11.38Mn/a2.8×n/a0.4×−102.3%0.3×n/a
Alaunos Therapeutics, Inc. · NASDAQ:TCRTUS$6.99MUS$6.37Mn/a2,124×n/a7.2×n/a0.0×0.90
Curanex Pharmaceuticals Inc · NASDAQ:CURXUS$6.92MUS$5.88Mn/an/an/a2.7×n/a0.2×0.84
Cambium Bio Ltd · ASX:CMBUS$6.82MUS$6.18Mn/a14.6×n/a4.3×−638.4%0.1×n/a
MetaVia Inc. · NASDAQ:MTVAUS$6.81M−US$1.97Mn/an/an/a2.8×n/a0.0×1.22
ZEO ScientifiX Inc. · OTC:ZEOXUS$6.51MUS$5.27Mn/a1.0×n/an/a−106.2%n/a0.54
FibroBiologics, Inc. · NASDAQ:FBLGUS$6.34MUS$5.17Mn/an/an/a3.5×n/a0.0×0.34
GT Biopharma, Inc. · NASDAQ:GTBPUS$6.33M−US$3.60Mn/an/an/a0.8×n/a0.0×1.57
Kyntra Bio, Inc. · NASDAQ:KYNBUS$6.32M−US$33.97Mn/a−6.4×n/an/a−326.0%n/a1.58
Acurx Pharmaceuticals, Inc. · NASDAQ:ACXPUS$6.30M−US$3.35Mn/an/an/a0.9×n/a0.0×1.31
Median of the othersUS$6.66MUS$5.22M2.8×2.8×−216.1%0.0×1.06

Forecasts

7 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.

Price target
52.38 USD · Analysts' mean
EPS, year to Dec 2026
-6.28 · 6 analysts
Revenue, year to Dec 2026
33.54M · 2 analysts

Team and board

Officers

OfficerRole
Lawrence M. BlattChairman, President, & Chief Executive Officer
Lesley Ann CalhounExecutive Vice President, Chief Operating Officer, and Chief Financial Officer
Jordyn TaraziVice President, Investor Relations & Corporate Communications
David B. SmithExecutive Vice President, Head of Chemical Operations
Jim HassardEVP, Chief Commercial Officer
Julian SymonsExecutive Vice President, Chief Scientific Officer
Kristina EngesethSenior Vice President, Head of People & Culture
Rámon PoloSenior Vice President, Head of Global Regulatory Affairs
Sushmita M. ChandaExecutive Vice President, Chief Development Officer
Tse-I LinSenior Vice President, Early Compound Development, Belgian Site Head

Board

DirectorRole
Lawrence M. BlattChairman, President, & Chief Executive Officer
Bridget MartellDirector
Carole NuechterleinDirector
Heather PrestonDirector
James ScopaDirector
K. Peter HirthDirector
Margarita ChavezDirector

Events

QuarterResultsShare move
Q3 2026Nov 6, 2026 · Before open−9.8%
Q2 2026Aug 6, 2026 · Before open+16.2%
Q1 2026May 8, 2026+3.0%
Q4 2025Mar 5, 2026 · Before open−2.9%
Q3 2025Nov 6, 2025 · Before open−3.1%
Q2 2025Aug 6, 2025 · After close+1.1%
Q1 2025May 6, 2025 · Before open−9.3%
Q4 2024Mar 10, 2025 · Before open−19.6%
Q3 2024Nov 6, 2024 · After close+6.1%
Q2 2024Aug 6, 2024 · After close+21.9%
All 20 quarters
QuarterResultsShare move
Q1 2024May 7, 2024 · After close−0.9%
Q4 2023Mar 12, 2024 · After close0.0%
Q3 2023Nov 2, 2023 · After close+1.3%
Q2 2023Aug 3, 2023 · After close−0.6%
Q1 2023May 4, 2023 · After close−8.8%
Q4 2022Mar 9, 2023 · After close−2.9%
Q3 2022Nov 2, 2022 · After close−1.9%
Q2 2022Aug 4, 2022 · After close+7.9%
Q1 2022May 4, 2022 · After close−11.3%
Q4 2021Mar 10, 2022 · After close+5.7%

Open Events

Decks

DeckKindSlidesDate
APASL 2025Conference19 slidesMarch 2025
Technical Presentation (November 2024)Technical19 slidesNov 1, 2024
Investor Presentation (October 2024)Investor deck43 slidesOctober 2024
Investor Presentation (August 2024)Investor deck41 slidesAugust 2024
Investor Presentation (June 2024)Investor deck43 slidesJune 2024
Investor Presentation (May 2024)Investor deck40 slidesMay 2024
Investor Presentation (April 2024)Investor deck40 slidesApril 2024
Investor Presentation (April 2024)Investor deck37 slidesApril 2024
Investor Presentation (March 2024)Investor deck35 slidesMarch 2024
Investor Presentation (February 2024)Investor deck44 slidesFebruary 2024
All 34 decks
DeckKindSlidesDate
Investor Presentation (January 2024)Investor deck43 slidesJanuary 2024
Investor Presentation (December 2023)Investor deck42 slidesDecember 2023
Investor Presentation (November 2023)Investor deck36 slidesNovember 2023
Investor Presentation (September 2023)Investor deck34 slidesSeptember 2023
Technical Presentation (May 2023)Technical14 slidesMay 2023
Investor Presentation (March 2023)Investor deck47 slidesMarch 2023
APASL 2023Conference13 slidesMarch 2023
APASL 2023Conference14 slidesFeb 1, 2023
Technical Presentation (February 2023)Technical20 slidesFeb 1, 2023
Technical Presentation (February 2023)Technical13 slidesFeb 1, 2023
Investor Presentation (January 2023)Investor deck47 slidesJan 24, 2023
J.P. Morgan 41st Annual Healthcare Conference 2023Conference43 slidesJanuary 2023
Investor Presentation (December 2022)Investor deck47 slidesDecember 2022
Investor Presentation (October 2022)Investor deck42 slidesOctober 2022
Investor Presentation (September 2022)Investor deck42 slidesSeptember 2022
J.P. Morgan 40th Annual Healthcare Conference 2022Conference42 slidesJan 10, 2022
Investor Presentation (November 2021)Investor deck49 slidesNov 18, 2021
Investor Presentation (August 2021)Investor deck54 slidesAugust 2021
Investor Presentation (July 2021)Investor deck50 slidesJul 14, 2021
Investor Presentation (June 2021)Investor deck42 slidesJune 2021
Investor Presentation (April 2021)Investor deck46 slidesApril 2021
JP Morgan 39th Annual Healthcare Conference 2021Conference35 slidesJan 11, 2021
Investor Presentation (November 2020)Investor deck35 slidesNovember 2020
Jefferies Healthcare Conference 2020Conference33 slidesJun 4, 2020

Open Decks

Financings

RaiseDate
Private placement of common stock, pre-funded warrants and accompanying warrants
Announced: about US$105M · US$26.0825 a share · Warrants at US$26.02 · Jefferies +2
Dealers: Jefferies, Piper Sandler, H.C. Wainwright & Co.
Use of proceeds: Advance ALG-000184 into a Phase 2 study in chronic hepatitis B and general corporate purposes
Feb 12, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$15.00 a share on Oct 15, 2020.

Price
US$15.00 a share
Shares offered
10,000,000 shares of common stock
Offering size
US$150 million
Underwriters' option
Up to 1,500,000 more shares
Underwriters
J.P. Morgan, Jefferies, Piper Sandler, Cantor · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceAug 26, 2020
Filed publiclySep 25, 2020
Amended onceOct 9, 2020
Shares registered with an exchangeOct 13, 2020
Declared effective by the SECOct 15, 2020
Final prospectus, with the priceOct 19, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Oct 19, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue2.19M3.61M6.19M00000
Cost of revenue930.0K2.62M3.07M3.67M104.2M3.33M2.30M1.29M
Gross profit1.26M3.94M15.5M13.9M4.36M-10.5M-2.30M-1.29M
Research and development69.5M70.3M73.0M85.1M104.2M79.9M44.0M10.5M
Selling, general and administrative20.7M22.8M30.6M26.4M28.5M17.9M10.0M3.21M
Operating income-88.0M-89.2M-88.1M-97.6M-128.3M-97.8M-54.0M-13.7M
Depreciation and amortization930.0K1.03M1.56M2.31M3.02M2.73M1.40M1.29M
EBITDA-87.1M-88.1M-86.6M-95.3M-125.3M-95.1M-52.6M-12.4M
Interest expense1.64M132.0K10.5M1.86M0
Income before tax-23.9M-130.9M-86.9M-95.9M-128.2M-108.4M-52.2M-13.9M
Income tax314.0K331.0K795.0K106.0K143.0K161.0K85.0K-272.0K
Net income-24.2M-131.2M-87.7M-96.0M-128.3M-108.5M-52.3M-13.9M
Earnings per share, basic-2.45-20.94-34.20-2.25-3.22-10.87-26.04-0.66
Earnings per share, diluted-2.45-20.94-34.20-2.25-3.22-10.87-26.04

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents18.3M37.0M135.7M81.3M186.8M220.4M69.6M24.0M
Short-term investments59.5M19.9M-70.0K44.5M3.92M23.1M48.1M66.8M
Current assets82.9M62.1M141.1M133.5M204.4M250.0M120.2M92.4M
Property, plant and equipment1.87M2.36M3.26M4.82M6.18M8.01M8.52M15.2M
Total assets88.5M70.1M151.5M146.7M235.4M265.3M146.5M107.7M
Accounts payable3.98M2.57M2.52M4.74M3.02M3.31M3.77M2.98M
Current liabilities21.2M21.7M23.9M33.1M39.0M30.3M13.8M7.49M
Total debt5.25M8.38M11.1M12.6M14.5M13.0M14.3M13.9M
Total liabilities35.0M99.1M59.4M42.8M50.6M45.3M29.3M121.5M
Shareholders' equity53.5M-29.0M92.1M103.9M184.7M220.0M-64.9M-13.7M
Shares outstanding6.18M3.86M3.00M42.9M42.7M38.1M3.93M21.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-82.5M-80.7M-79.0M-79.4M-115.7M-74.3M-46.8M-6.05M
Capital spending-437.0K-130.0K-19.0K-943.0K-892.0K-2.06M-2.79M-2.52M
Free cash flow-82.9M-80.9M-79.0M-80.3M-116.6M-76.3M-49.6M-8.56M
Cash from investing-37.8M-18.3M45.0M-26.3M3.02M32.8M6.79M-69.3M
Cash from financing101.6M355.0K88.3M164.0K78.7M192.3M85.5M99.9M
Share buybacks225.0K79.6M156.9M
Change in cash-18.7M-98.7M54.3M-105.5M-34.0M150.8M45.6M24.5M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2026Quarterly reportSEC
8-K · Current reportNov 6, 2026ResultsSEC
8-K · Current reportSep 15, 2026Material contractSEC
S-8 · Registration statement for employee plansAug 6, 2026Offer documentSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
8-K · Current reportJun 26, 2026Management or board changeSEC
SCHEDULE 13D · Big-stake noticeJun 24, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
DEFA14A · Additional proxy materialApr 29, 2026Meeting noticeSEC
ARS · Annual report to shareholdersApr 29, 2026Annual reportSEC
DEF 14A · Proxy statementApr 29, 2026Meeting noticeSEC
8-K · Current reportApr 21, 2026Material contractSEC
8-K · Current reportApr 14, 2026Current reportSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMar 5, 2026Offer documentSEC
10-K · Annual reportMar 5, 2026Annual reportSEC
8-K · Current reportMar 5, 2026ResultsSEC
3 · Initial statement of ownershipFeb 19, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 11, 2026Big-stake noticeSEC
8-K · Current reportFeb 4, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 13, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansAug 6, 2025Offer documentSEC
10-Q · Quarterly reportAug 6, 2025Quarterly reportSEC
8-K · Current reportAug 6, 2025ResultsSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
8-K · Current reportJun 26, 2025Management or board changeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 6, 2025Quarterly reportSEC
8-K · Current reportMay 6, 2025ResultsSEC
DEFA14A · Additional proxy materialApr 28, 2025Meeting noticeSEC
ARS · Annual report to shareholdersApr 28, 2025Annual reportSEC
DEF 14A · Proxy statementApr 28, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 16, 2025Meeting noticeSEC
EFFECT · Notice that a registration is effectiveApr 4, 2025Other filingsSEC
424B3 · ProspectusApr 3, 2025Offer documentSEC
CORRESP · Letter to the SECApr 1, 2025Other filingsSEC
UPLOAD · Letter from the SECApr 1, 2025Other filingsSEC
S-3 · Registration statementMar 27, 2025Offer documentSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 12, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansMar 10, 2025Offer documentSEC
10-K · Annual reportMar 10, 2025Annual reportSEC
8-K · Current reportMar 10, 2025ResultsSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
DFeb 28, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
8-K · Current reportFeb 12, 2025Material contractSEC
8-K · Current reportFeb 3, 2025Management or board changeSEC
EFFECT · Notice that a registration is effectiveNov 19, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
CORRESP · Letter to the SECNov 14, 2024Other filingsSEC
UPLOAD · Letter from the SECNov 13, 2024Other filingsSEC
SC 13G · Big-stake noticeNov 12, 2024Big-stake noticeSEC
S-8 · Registration statement for employee plansNov 6, 2024Offer documentSEC
S-3 · Registration statementNov 6, 2024Offer documentSEC
10-Q · Quarterly reportNov 6, 2024Quarterly reportSEC
8-K · Current reportNov 6, 2024ResultsSEC
4 · Change in ownershipOct 10, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 26, 2024Insider tradeSEC
SC 13G · Big-stake noticeSep 12, 2024Big-stake noticeSEC
4 · Change in ownershipSep 6, 2024Insider tradeSEC
4 · Change in ownershipSep 6, 2024Insider tradeSEC
4 · Change in ownershipSep 6, 2024Insider tradeSEC
8-K · Current reportSep 5, 2024Current reportSEC
8-K · Current reportAug 19, 2024Current reportSEC
4 · Change in ownershipAug 9, 2024Insider tradeSEC
4 · Change in ownershipAug 9, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 9, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 9, 2024Insider tradeSEC
8-K · Current reportAug 8, 2024Management or board changeSEC
10-Q · Quarterly reportAug 6, 2024Quarterly reportSEC
8-K · Current reportAug 6, 2024ResultsSEC
4 · Change in ownershipJun 28, 2024Insider tradeSEC
4 · Change in ownershipJun 28, 2024Insider tradeSEC
4 · Change in ownershipJun 28, 2024Insider tradeSEC
4 · Change in ownershipJun 28, 2024Insider tradeSEC
8-K · Current reportJun 28, 2024Management or board changeSEC
8-K · Current reportMay 31, 2024Current reportSEC
8-K · Current reportMay 22, 2024Management or board changeSEC
8-K · Current reportMay 15, 2024Management or board changeSEC
10-Q · Quarterly reportMay 7, 2024Quarterly reportSEC
8-K · Current reportMay 7, 2024ResultsSEC
ARS · Annual report to shareholdersApr 29, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 16, 2024Meeting noticeSEC
S-8 · Registration statement for employee plansMar 12, 2024Offer documentSEC
10-K · Annual reportMar 12, 2024Annual reportSEC
8-K · Current reportMar 12, 2024ResultsSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
4 · Change in ownershipFeb 28, 2024Insider tradeSEC
4 · Change in ownershipFeb 28, 2024Insider tradeSEC
4 · Change in ownershipFeb 28, 2024Insider tradeSEC
4 · Change in ownershipFeb 28, 2024Insider tradeSEC
4 · Change in ownershipFeb 28, 2024Insider tradeSEC
4 · Change in ownershipFeb 28, 2024Insider tradeSEC
4 · Change in ownershipFeb 28, 2024Insider tradeSEC
4 · Change in ownershipFeb 28, 2024Insider tradeSEC
4 · Change in ownershipFeb 28, 2024Insider tradeSEC
8-K · Current reportFeb 28, 2024Management or board changeSEC
SC TO-I/AFeb 28, 2024Acquisition or disposalSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedFeb 8, 2024Big-stake noticeSEC
SC TO-IJan 30, 2024Acquisition or disposalSEC
SC TO-CJan 25, 2024Other filingsSEC
8-K · Current reportJan 25, 2024Current reportSEC
424B3 · ProspectusNov 28, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveNov 28, 2023Other filingsSEC
CORRESP · Letter to the SECNov 22, 2023Other filingsSEC
8-K · Current reportNov 22, 2023Management or board changeSEC
UPLOAD · Letter from the SECNov 21, 2023Other filingsSEC
S-3 · Registration statementNov 17, 2023Offer documentSEC
8-K · Current reportNov 15, 2023Management or board changeSEC
SC 13G/A · Big-stake notice, amendedNov 7, 2023Big-stake noticeSEC
3 · Initial statement of ownershipNov 7, 2023Insider tradeSEC
DNov 7, 2023Other filingsSEC
SC 13D · Big-stake noticeNov 6, 2023Big-stake noticeSEC
10-Q · Quarterly reportNov 2, 2023Quarterly reportSEC
SC 13G · Big-stake noticeNov 2, 2023Big-stake noticeSEC
8-K · Current reportNov 2, 2023ResultsSEC
4 · Change in ownershipOct 27, 2023Insider tradeSEC
4 · Change in ownershipOct 27, 2023Insider tradeSEC
4 · Change in ownershipOct 27, 2023Insider tradeSEC
8-K · Current reportOct 25, 2023Material contractSEC
8-K · Current reportOct 18, 2023Current reportSEC
4 · Change in ownershipSep 12, 2023Insider tradeSEC
4 · Change in ownershipSep 12, 2023Insider tradeSEC
4 · Change in ownershipSep 12, 2023Insider tradeSEC
4 · Change in ownershipSep 12, 2023Insider tradeSEC
4 · Change in ownershipSep 12, 2023Insider tradeSEC
8-K · Current reportSep 7, 2023Current reportSEC
10-Q · Quarterly reportAug 3, 2023Quarterly reportSEC
8-K · Current reportAug 3, 2023ResultsSEC
8-K · Current reportAug 1, 2023Current reportSEC
8-K · Current reportJul 25, 2023Meeting outcomeSEC
4 · Change in ownershipJul 21, 2023Insider tradeSEC
4 · Change in ownershipJul 21, 2023Insider tradeSEC
4 · Change in ownershipJul 21, 2023Insider tradeSEC
4 · Change in ownershipJul 21, 2023Insider tradeSEC
4 · Change in ownershipJul 21, 2023Insider tradeSEC
DEFR14AJun 2, 2023Meeting noticeSEC
10-Q · Quarterly reportMay 4, 2023Quarterly reportSEC
8-K · Current reportMay 4, 2023ResultsSEC
ARS · Annual report to shareholdersApr 28, 2023Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2023Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2023Meeting noticeSEC
4 · Change in ownershipMar 17, 2023Insider tradeSEC
4 · Change in ownershipMar 17, 2023Insider tradeSEC
4 · Change in ownershipMar 17, 2023Insider tradeSEC
4 · Change in ownershipMar 17, 2023Insider tradeSEC
4 · Change in ownershipMar 17, 2023Insider tradeSEC
4 · Change in ownershipMar 17, 2023Insider tradeSEC
S-8 · Registration statement for employee plansMar 9, 2023Offer documentSEC
10-K · Annual reportMar 9, 2023Annual reportSEC
8-K · Current reportMar 9, 2023ResultsSEC

This page holds 200 of 350 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Aligos Therapeutics, Inc.’s releases · as of Feb 12, 2025

Common shares
5,444,558
Fully diluted
5,444,558

Fully diluted

LineShares
Common shares5,444,558

Share count over time

CountShares
Nov 22, 20265,444,558

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Deep Track Capital, LP444K8.2%US$2.5MSep 30, 2026
Sio Capital Management, LLC327K6.0%US$1.84MSep 30, 2026
Parkman Healthcare Partners LLC326K6.0%US$1.83MSep 30, 2026
Marshall Wace, LLP247K4.5%US$1.39MSep 30, 2026
Vanguard204K3.7%US$1.15MSep 30, 2026
Schonfeld Strategic Advisors LLC182K3.3%US$1.02MSep 30, 2026
Woodline Partners LP177K3.3%US$999KSep 30, 2026
Baker Bros. Advisors LP83,0551.5%US$468KSep 30, 2026
Hhlr Advisors, LTD.76,2471.4%US$429KSep 30, 2026
D. E. Shaw & Co., Inc.71,5281.3%US$403KSep 30, 2026
All 35 holders
HolderSharesOf the companyValueAs of
UBS67,2981.2%US$379KSep 30, 2026
Geode Capital50,3100.92%US$283KSep 30, 2026
Prudential Financial Inc45,3540.83%US$255KSep 30, 2026
LPL Financial LLC38,1700.70%US$215KSep 30, 2026
BlackRock29,5360.54%US$166KSep 30, 2026
Two Sigma27,5220.51%US$155KSep 30, 2026
Dimensional21,0440.39%US$118KSep 30, 2026
Gsa Capital Partners LLP20,7140.38%US$117KSep 30, 2026
Trexquant Investment LP19,3950.36%US$109KSep 30, 2026
Verition Fund Management LLC18,8870.35%US$106KSep 30, 2026
Renaissance Technologies15,1000.28%US$85,013Sep 30, 2026
Quadrature Capital Ltd13,4060.25%US$75,476Sep 30, 2026
Citadel11,5390.21%US$64,965Sep 30, 2026
Rockefeller Capital Management L.P.10,2760.19%US$57,854Sep 30, 2026
Federation des caisses Desjardins du Quebec3,3000.06%US$18,579Sep 30, 2026
Golden State Wealth Management, LLC2,6740.05%US$15,055Sep 30, 2026
RBC2,2310.04%US$13,000Sep 30, 2026
Morgan Stanley205<0.01%US$1,154Sep 30, 2026
Osaic Holdings, Inc.200<0.01%US$1,124Sep 30, 2026
SBI Securities Co., Ltd.26<0.01%US$146Sep 30, 2026
JPMorgan26<0.01%US$146Sep 30, 2026
Tower Research Capital LLC (TRC)5<0.01%US$28Sep 30, 2026
Elevation Wealth Partners, LLC4<0.01%US$23Sep 30, 2026
BNP Paribas3<0.01%US$17Sep 30, 2026
Barclays1<0.01%US$6Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund129K2.4%US$743KJun 30, 2026
Vanguard Extended Market Index Fund46,7730.86%US$270KJun 30, 2026
Fidelity Extended Market Index Fund24,8090.46%US$141KMay 31, 2026
iShares Micro-Cap ETF16,4280.30%US$94,790Jun 30, 2026
U.S. Micro Cap Portfolio8,3290.15%US$35,232Jul 31, 2026
Fidelity Total Market Index Fund7,5530.14%US$43,052May 31, 2026
Fidelity Series Total Market Index Fund6,1410.11%US$35,004May 31, 2026
U.S. Small Cap Portfolio3,5730.07%US$15,114Jul 31, 2026
Fidelity Nasdaq Composite Index Fund3,5690.07%US$20,343May 31, 2026
Strategic Advisers U.S. Total Stock Fund3,2000.06%US$18,240May 31, 2026
All 18 holders
HolderSharesOf the companyValueAs of
Dimensional U.S. Small Cap ETF2,8100.05%US$11,886Jul 31, 2026
U.S. Vector Equity Portfolio2,0930.04%US$8,853Jul 31, 2026
Dimensional U.S. Core Equity 2 ETF1,8550.03%US$7,847Jul 31, 2026
Avantis U.S. Small Cap Equity ETF1,4270.03%US$8,134May 31, 2026
Dimensional US Sustainability Core 1 ETF1,1490.02%US$4,860Jul 31, 2026
1290 VT Micro Cap Portfolio1,0900.02%US$6,289Jun 30, 2026
Avantis U.S. Small Cap Equity Fund332<0.01%US$1,892May 31, 2026
Total Stock Market Index Trust178<0.01%US$1,027Jun 30, 2026

Big stakes

StakeStakeSharesDateFiling
Alyeska Investment Group, L.P.5.64%352KSep 30, 2026Schedule 13G
Lawrence M. Blatt5.60%316KJun 16, 2026Schedule 13D
Sio Capital Management, LLC5.46%336KDec 31, 2025Schedule 13G
Parkman Healthcare Partners LLC5.20%326KSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Heather Preston
Other companies: Oxford Nanopore Technologies PLC (Non Executive Director · Since at least May 1, 2026); Akouos Inc (Director · Jun 25, 2020 – Nov 30, 2022 · Past); Fusion Pharmaceuticals Inc (Director · Jun 25, 2020 – Jun 14, 2023 · Past); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Jun 24, 2021 · Past); Entasis Therapeutics Holdings Inc (Director · Sep 25, 2018 – Jun 19, 2019 · Past); Albireo Pharma Inc (Director · Nov 3, 2016 – Jan 23, 2017 · Past); Otonomy Inc (Director · Aug 12, 2014 – Jun 11, 2019 · Past); Alder BioPharmaceuticals Inc (Director · May 7, 2014 – Oct 22, 2019 · Past)
Director · Since at least Aug 7, 2024
Bridget Martell
Other companies: Delcath Systems, Inc. (Director · Since at least May 23, 2024); Achieve Life Sciences, Inc. (Director · Since at least Mar 15, 2021); Ayala Pharmaceuticals Inc (Director · Oct 18, 2023 – Oct 18, 2023 · Past); POINT Biopharma Global Inc (Director · Jun 12, 2023 – Jun 13, 2023 · Past); Kura Oncology, Inc. (Acting Chief Medical Officer · Feb 10, 2020 – Aug 24, 2020 · Past)
Director · Since at least Nov 16, 2021
Jack Nielsen
Other companies: ALX Oncology Holdings Inc. (Director · Jun 15, 2022 – Jun 20, 2023 · Past); Instil Bio, Inc. (Director · May 20, 2022 – Jun 14, 2023 · Past); Harmony Biosciences Holdings, Inc. (Director · Mar 30, 2022 – May 29, 2024 · Past)
Director · Jun 23, 2022 – Feb 27, 2024 · Past
Kathleen Sereda Glaub
Other companies: Codexis, Inc. (Director · Jun 11, 2019 – Jun 11, 2019 · Past)
Director · Oct 15, 2020 – Oct 15, 2020 · Past
K. Peter Hirth
Other companies: Vaxcyte, Inc. (Director · Jun 11, 2020 – Jun 6, 2024 · Past)
Director · Since at least Oct 15, 2020
Carole NuechterleinDirector · Since at least Nov 5, 2026
David B. SmithExecutive Vice President, Head of Chemical Operations · Since at least Dec 11, 2025
James ScopaDirector · Since at least Nov 5, 2026
Jim HassardEVP, Chief Commercial Officer · Since at least Jan 13, 2026
Jordyn TaraziVice President, Investor Relations & Corporate Communications · Since at least Oct 5, 2026
All 20 people
PersonSeat
Julian SymonsExecutive Vice President, Chief Scientific Officer · Since at least Oct 15, 2020
Kristina EngesethSenior Vice President, Head of People & Culture · Since at least Nov 4, 2026
Lawrence M. BlattPresident and CEO, Director · Since at least Jul 16, 2025
Lesley Ann CalhounExecutive Vice President, Chief Operating Officer, and Chief Financial Officer · Since at least May 20, 2025
Lucinda Y QuanSee Remarks · Oct 15, 2020 – Sep 8, 2023 · Past
Margarita ChavezDirector · Since at least Aug 7, 2024
Matthew W McClureChief Medical Officer · Apr 27, 2022 – Mar 1, 2024 · Past
Rámon PoloSenior Vice President, Head of Global Regulatory Affairs · Since at least Aug 20, 2025
Sushmita M. ChandaExecutive Vice President, Chief Development Officer · Since at least Aug 20, 2025
Tse-I LinSenior Vice President, Early Compound Development, Belgian Site Head · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Aligos Therapeutics, Inc.